- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03939338
Recruitment Status Recruiting
First Posted May 6, 2019
Last update posted June 26, 2019
This study aims to determine whether combination with regulatory T cell (Treg) levels and cardiac magnetic resonance imaging (CMR) are predictive of the severity of reperfusion injury following myocardial infarction and the prognosis in STEMI patients receiving primary percutaneous coronary intervention (PPCI).
Other: Treg levels and CMR results
This is an observational study. Exposure: Different Treg levels and CMR results.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Confirmed STEMI diagnosis
- Undergoing primary percutaneous coronary intervention (presenting <12 hours after symptom onset) - Patients were able to complete cardiac magnetic resonance imaging (CMR) and speckle tracking imaging echocardiogram (STE) examinations - Patients agreed and provided informed consent Exclusion Criteria: - Previous myocardial infarction or revascularization (PCI or CABG) - Congestive heart failure with LVEF<40% - Atrial fibrillation - Renal insufficiency (GFR < 30 ml/min/1.73m^2) - Acute infectious diseases within nearly 3 months - Rheumatic immune system diseases - Malignant tumors - Claustrophobia - Contraindicated to CMR - Patients do not agree to be included in the study
Contact: Hongwei Li, M.D. 0086 10 63139780 email@example.com
Beijing Friendship Hospital, Capital Medical University
Beijing Friendship Hospital